In one trial, staying on it cut six-month relapse by eight points
Among 426 people who had already recovered on a standardised extract, 18.1 percent relapsed over 26 weeks against 25.7 percent on placebo. It is the only long-term test it has had.
What the study found
Staying on it after recovery cut six-month relapse by eight points
Among 426 people who had already recovered on a standardised extract, 18.1 percent relapsed over the following 26 weeks on the extract against 25.7 percent on placebo. The average delay to relapse was 14 days. It is the only long-term test the herb has had.
The caveat · Two authors linked to the maker
Everyone randomised had already responded during a six-week run-in, so the result describes people it was working for rather than anyone starting out. The significance test was one-sided. Two of the five authors are connected to the company that makes the extract.